II 

111TH CONGRESS 

1ST SESSION S. 1492 

To amend the Public Health Service Act to fund breakthroughs in Alzheimer’s 

disease research while providing more help to caregivers and increasing 

public education about prevention. 

IN THE SENATE OF THE UNITED STATES 

JULY 22, 2009 

Mr. REID (for Ms. MIKULSKI (for herself, Mr. BOND, Mrs. GILLIBRAND, Mr. 

MENENDEZ, Mr. BURR, and Ms. COLLINS)) introduced the following bill; 

which was read twice and referred to the Committee on Health, Education, Labor, and Pensions 

A BILL 

To amend the Public Health Service Act to fund breakthroughs in Alzheimer’s disease research while providing 

more help to caregivers and increasing public education 

about prevention. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Alzheimer’s Break5 through Act of 2009’’. 

6 SEC. 2. FINDINGS. 

7 Congress makes the following findings: 


wwoods2 on DSK1DXX6B1PROD with BILLS
2 

•S 1492 IS

1 (1) Alzheimer’s disease is a disorder that de2 stroys cells in the brain. The disease is the leading 

3 cause of dementia, a condition that involves gradual 

4 memory loss, decline in the ability to perform rou5 tine tasks, disorientation, difficulty in learning, loss 

6 of language skills, impairment of judgment, and per7 sonality changes. As the disease progresses, people 

8 with Alzheimer’s disease become unable to care for 

9 themselves. The loss of brain cells eventually leads 

10 to the failure of other systems in the body. 

11 (2) An estimated 5,300,000 Americans have 

12 Alzheimer’s disease and 1 in 10 individuals has a 

13 family member with the disease. By 2050, the num14 ber of individuals with the disease could reach 

15 16,000,000 unless science finds a way to prevent or 

16 cure the disease. 

17 (3) One in 8 people over the age of 65, and 

18 nearly half of those over the age of 85 have Alz19 heimer’s disease. Younger people also get the dis20 ease. 

21 (4) The Alzheimer’s disease process may begin 

22 in the brain as many as 20 years before the symp23 toms of Alzheimer’s disease appear. An individual 

24 will live an average of 4 to 6 years, and as many as 


wwoods2 on DSK1DXX6B1PROD with BILLS
3 

•S 1492 IS

1 20 years, once the symptoms of Alzheimer’s disease 

2 appear. 

3 (5) In 2005, Medicare alone spent 

4 $91,000,000,000 for the care of individuals with 

5 Alzheimer’s disease and this amount is projected to 

6 increase to $160,000,000,000 in 2010. 

7 (6) Ninety-five percent of Medicare beneficiaries 

8 with Alzheimer’s disease have one or more other 

9 chronic conditions that are common in the elderly, 

10 such as coronary heart disease (26 percent), conges11 tive heart failure (16 percent), diabetes (23 percent), 

12 and chronic obstructive pulmonary disease (15 per13 cent). 

14 (7) Seven in 10 individuals with Alzheimer’s 

15 disease live at home. Cost for care at home is higher 

16 for people with Alzheimer’s disease than other indi17 viduals. Almost all families pay some out-of-pocket 

18 costs. 

19 (8) Half of all nursing home residents have Alz20 heimer’s disease or a related disorder. The average 

21 annual cost of Alzheimer’s disease nursing home 

22 care is more than $77,000. Medicaid pays half of 

23 the total nursing home bill and helps 2 out of 3 resi24 dents pay for their care. Medicaid expenditures for 

25 nursing home care for people with Alzheimer’s disVerDate Nov 24 2008 03:06 Jul 23, 2009 Jkt 079200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S1492.IS S1492

wwoods2 on DSK1DXX6B1PROD with BILLS
4 

•S 1492 IS

1 ease are estimated to increase from $21,000,000,000 

2 in 2005 to $24,000,000,000 in 2010. 

3 (9) In fiscal year 2007, the Federal Govern4 ment spent an estimated $411,000,000 on Alz5 heimer’s disease research. Over the next 40 years, 

6 Alzheimer’s disease-related costs to Medicare and 

7 Medicaid alone are projected to total 

8 $20,000,000,000,000 in constant dollars, rising to 

9 over $1,000,000,000,000 per year by 2050. This 

10 amounts to less than a penny spent on Alzheimer’s 

11 disease research for each dollar that the Federal 

12 Government spends on Alzheimer’s disease-related 

13 costs each year. 

14 (10) It is estimated that the annual value of the 

15 informal care system is $94,000,000,000. Family 

16 caregiving comes at enormous physical, emotional, 

17 and financial sacrifice, putting the whole system at 

18 risk. 

19 (11) Almost 60 percent of caregivers of individ20 uals with Alzheimer’s disease are women, and over 

21 one-fourth have children or grandchildren under the 

22 age of 18 living at home. Caregiving leaves them less 

23 time for other family members and they are much 

24 more likely to report family conflicts because of their 

25 caregiving role. 


wwoods2 on DSK1DXX6B1PROD with BILLS
5 

•S 1492 IS

1 (12) Most Alzheimer’s disease caregivers work 

2 outside the home before beginning their caregiving 

3 careers, but caregiving forces them to miss work, cut 

4 back to part-time, take less demanding jobs, choose 

5 early retirement, or give up work altogether. As a 

6 result, in 2002, Alzheimer’s disease cost American 

7 business an estimated $36,500,000,000 in lost pro8 ductivity, as well as an additional $24,600,000,000 

9 in business contributions to the total cost of care. 

10 TITLE I—INCREASING THE FED11 ERAL COMMITMENT TO ALZ12 HEIMER’S RESEARCH 

13 SEC. 101. DOUBLING NIH FUNDING FOR ALZHEIMER’S DIS14 EASE RESEARCH. 

15 For the purpose of conducting and supporting re16 search on Alzheimer’s disease (including related activities 

17 under subpart 5 of part C of title IV of the Public Health 

18 Service Act (42 U.S.C. 285e et seq.)), there are authorized 

19 to be appropriated $2,000,000,000 for fiscal year 2010, 

20 and such sums as may be necessary for each of fiscal years 

21 2011 through 2014. 

22 SEC. 102. PRIORITY TO ALZHEIMER’S DISEASE RESEARCH. 

23 Section 443 of the Public Health Service Act (42 

24 U.S.C. 285e) is amended— 


wwoods2 on DSK1DXX6B1PROD with BILLS
6 

•S 1492 IS

1 (1) by striking ‘‘The general’’ and inserting the 

2 following: 

3 ‘‘(a) IN GENERAL.—The general;’’ and 

4 (2) by adding at the end the following: 

5 ‘‘(b) PRIORITIES.—The Director of the Institute 

6 shall, in expending amounts appropriated to carry out this 

7 subpart, give priority to conducting and supporting Alz8 heimer’s disease research.’’. 

9 SEC. 103. ALZHEIMER’S DISEASE PREVENTION INITIATIVE. 

10 Section 443 of the Public Health Service Act (42 

11 U.S.C. 285e), as amended by section 102, is further 

12 amended by adding at the end the following: 

13 ‘‘(c) PREVENTION TRIALS.—The Director of the In14 stitute shall increase the emphasis on the need to conduct 

15 Alzheimer’s disease prevention trials within the National 

16 Institutes of Health. 

17 ‘‘(d) NEUROSCIENCE INITIATIVE.—The Director of 

18 the Institute shall ensure that Alzheimer’s disease is main19 tained as a high priority for the neuroscience initiative of 

20 the National Institutes of Health.’’. 

21 SEC. 104. ALZHEIMER’S DISEASE CLINICAL RESEARCH. 

22 (a) CLINICAL RESEARCH.—Subpart 5 of part C of 

23 title IV of the Public Health Service Act (42 U.S.C. 285e 

24 et seq.) is amended by adding at the end the following: 


wwoods2 on DSK1DXX6B1PROD with BILLS
7 

•S 1492 IS

1 ‘‘SEC. 445J. ALZHEIMER’S DISEASE CLINICAL RESEARCH. 

2 ‘‘(a) IN GENERAL.—The Director of the Institute, 

3 pursuant to section 444(d), shall conduct and support co4 operative clinical research regarding Alzheimer’s disease. 

5 Such research shall include— 

6 ‘‘(1) investigating therapies, interventions, and 

7 agents to detect, treat, slow the progression of, or 

8 prevent Alzheimer’s disease; 

9 ‘‘(2) enhancing the national infrastructure for 

10 the conduct of clinical trials on Alzheimer’s disease; 

11 ‘‘(3) developing and testing novel approaches to 

12 the design and analysis of such trials; 

13 ‘‘(4) facilitating the enrollment of patients for 

14 such trials, including patients from diverse popu15 lations; 

16 ‘‘(5) developing improved diagnostics and 

17 means of patient assessment for Alzheimer’s disease; 

18 ‘‘(6) the conduct of clinical trials on potential 

19 therapies, including readily available compounds 

20 such as herbal remedies and other alternative treat21 ments; 

22 ‘‘(7) research to develop better methods of early 

23 diagnosis, including the use of current imaging tech24 niques; and 

25 ‘‘(8) other research, as determined appropriate 

26 by the Director of the Institute after consultation 


wwoods2 on DSK1DXX6B1PROD with BILLS
8 

•S 1492 IS

1 with the Alzheimer’s disease centers and Alzheimer’s 

2 disease research centers established under section 

3 445. 

4 ‘‘(b) EARLY DIAGNOSIS AND DETECTION RE5 SEARCH.— 

6 ‘‘(1) IN GENERAL.—The Director of the Insti7 tute, in consultation with the directors of other rel8 evant institutes and centers of the National Insti9 tutes of Health, shall conduct, or make grants for 

10 the conduct of, research related to the early detec11 tion, diagnosis, and prevention of Alzheimer’s dis12 ease and of mild cognitive impairment or other po13 tential precursors to Alzheimer’s disease. 

14 ‘‘(2) EVALUATION.—The research described in 

15 paragraph (1) may include the evaluation of diag16 nostic tests and imaging techniques. 

17 ‘‘(3) STUDY.—Not later than 1 year after the 

18 date of enactment of this section, the Director of the 

19 Institute, in cooperation with the heads of other rel20 evant Federal agencies, shall conduct a study, and 

21 submit to Congress a report, to estimate the number 

22 of individuals with early-onset Alzheimer’s disease 

23 (those diagnosed before the age of 65) and related 

24 dementias in the United States, the causes of early25 onset dementia, and the unique problems faced by 


wwoods2 on DSK1DXX6B1PROD with BILLS
9 

•S 1492 IS

1 such individuals, including problems accessing gov2 ernment services. 

3 ‘‘(c) VASCULAR DISEASE.—The Director of the Insti4 tute, in consultation with the directors of other relevant 

5 institutes and centers of the National Institutes of Health, 

6 shall conduct, or make grants for the conduct of, research 

7 related to the relationship of vascular disease and Alz8 heimer’s disease, including clinical trials to determine 

9 whether drugs developed to prevent cerebrovascular dis10 ease can prevent the onset or progression of Alzheimer’s 

11 disease. 

12 ‘‘(d) TREATMENTS AND PREVENTION.—The Director 

13 of the Institute shall place special emphasis on expediting 

14 the translation of research findings under this section into 

15 effective treatments and prevention strategies for individ16 uals at risk of Alzheimer’s disease and other dementias. 

17 ‘‘(e) NATIONAL ALZHEIMER’S COORDINATING CEN18 TER.—The Director of the Institute may establish a Na19 tional Alzheimer’s Coordinating Center to facilitate col20 laborative research among the Alzheimer’s Disease Cen21 ters and Alzheimer’s Disease Research Centers established 

22 under section 445.’’. 

23 (b) ALZHEIMER’S DISEASE CENTERS.—Section 

24 445(a)(1) of the Public Health Service Act (42 U.S.C. 

25 285e–2(a)(1)) is amended by inserting ‘‘, outcome measVerDate Nov 24 2008 03:06 Jul 23, 2009 Jkt 079200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6201 E:\BILLS\S1492.IS S1492

wwoods2 on DSK1DXX6B1PROD with BILLS
10 

•S 1492 IS

1 ures, and disease management,’’ after ‘‘treatment meth2 ods’’. 

3 SEC. 105. RESEARCH ON ALZHEIMER’S DISEASE 

4 CAREGIVING. 

5 Section 445C of the Public Health Service Act (42 

6 U.S.C. 285e–5) is amended— 

7 (1) by striking ‘‘SEC. 445C. RESEARCH PRO8 GRAM AND PLAN (a)’’ and inserting the following: 

9 ‘‘SEC. 445C. RESEARCH ON ALZHEIMER’S DISEASE SERV10 ICES AND CAREGIVING. 

11 ‘‘(a) SERVICES RESEARCH.—’’; 

12 (2) by striking subsections (b), (c), and (e); 

13 (3) by inserting after subsection (a) the fol14 lowing: 

15 ‘‘(b) INTERVENTIONS RESEARCH.—The Director of 

16 the Institute shall, in collaboration with the directors of 

17 the other relevant institutes and centers of the National 

18 Institutes of Health, conduct, or make grants for the con19 duct of, clinical, social, and behavioral research related to 

20 interventions designed to help caregivers of patients with 

21 Alzheimer’s disease and other dementias and improve pa22 tient outcomes.’’; 

23 (4) by redesignating subsection (d) as sub24 section (c); and 


wwoods2 on DSK1DXX6B1PROD with BILLS
11 

•S 1492 IS

1 (5) in subsection (c) (as redesignated by para2 graph (4)), by striking ‘‘the Director’’ and inserting 

3 ‘‘MODEL CURRICULA AND TECHNIQUES.—The Di4 rector’’. 

5 SEC. 106. NATIONAL SUMMIT ON ALZHEIMER’S DISEASE. 

6 (a) IN GENERAL.—Not later than 3 years after the 

7 date of enactment of this Act, and every 3 years there8 after, the Secretary of Health and Human Services (re9 ferred to in this section as the ‘‘Secretary’’) shall convene 

10 a National Summit on Alzheimer’s Disease to— 

11 (1) provide a detailed overview of current re12 search activities relating to Alzheimer’s disease at 

13 the National Institutes of Health; and 

14 (2) discuss and solicit input related to potential 

15 areas of collaboration between the National Insti16 tutes of Health and other Federal health agencies, 

17 including the Centers for Disease Control and Pre18 vention, the Administration on Aging, the Agency 

19 for Healthcare Research and Quality, and the 

20 Health Resources and Services Administration, re21 lated to research, prevention, and treatment of Alz22 heimer’s disease. 

23 (b) PARTICIPANTS.—The summit convened under 

24 subsection (a) shall include researchers, representatives of 

25 academic institutions, Federal and State policymakers, 


wwoods2 on DSK1DXX6B1PROD with BILLS
12 

•S 1492 IS

1 public health professionals, and representatives of vol2 untary health agencies as participants. 

3 (c) FOCUS AREAS.—The summit convened under 

4 subsection (a) shall focus on— 

5 (1) a broad range of Alzheimer’s disease re6 search activities relating to biomedical research, pre7 vention research, and caregiving issues; 

8 (2) clinical research for the development and 

9 evaluation of new treatments for Alzheimer’s dis10 ease; 

11 (3) translational research on evidence-based and 

12 cost-effective best practices in the treatment and 

13 prevention of Alzheimer’s disease; 

14 (4) information and education programs for 

15 health care professionals and the public relating to 

16 Alzheimer’s disease; 

17 (5) priorities among the programs and activities 

18 of the various Federal agencies regarding Alz19 heimer’s disease and other dementias; and 

20 (6) challenges and opportunities for scientists, 

21 clinicians, patients, and voluntary organizations re22 lating to Alzheimer’s disease. 

23 (d) REPORT.—Not later than 180 days after the date 

24 on which the summit is convened under subsection (a), 

25 the Director of the National Institutes of Health shall preVerDate Nov 24 2008 03:06 Jul 23, 2009 Jkt 079200 PO 00000 Frm 00012 Fmt 6652 Sfmt 6201 E:\BILLS\S1492.IS S1492

wwoods2 on DSK1DXX6B1PROD with BILLS
13 

•S 1492 IS

1 pare and submit to the appropriate committees of Con2 gress a report that includes a summary of the proceedings 

3 of the summit and a description of Alzheimer’s disease re4 search, education, and other activities that are conducted 

5 or supported through the National Institutes of Health. 

6 (e) PUBLIC INFORMATION.—The Secretary shall 

7 make readily available to the public information about the 

8 research, education, and other activities relating to Alz9 heimer’s disease and other related dementias, that are 

10 conducted or supported by the National Institutes of 

11 Health. 

12 TITLE II—PUBLIC HEALTH PRO13 MOTION AND PREVENTION 

14 OF ALZHEIMER’S DISEASE 

15 SEC. 201. ENHANCING PUBLIC HEALTH ACTIVITIES RE16 LATED TO COGNITIVE HEALTH, ALZHEIMER’S 

17 DISEASE, AND OTHER DEMENTIAS. 

18 Part P of title III of the Public Health Service Act 

19 (42 U.S.C. 280g et seq.) is amended— 

20 (1) by redesignating the second and third sec21 tions 399R as sections 399S and 399T, respectively; 

22 and 

23 (2) by adding at the end the following: 


wwoods2 on DSK1DXX6B1PROD with BILLS
14 

•S 1492 IS

1 ‘‘SEC. 399U. ALZHEIMER’S DISEASE PUBLIC EDUCATION 

2 CAMPAIGN. 

3 ‘‘(a) IN GENERAL.—The Secretary, acting through 

4 the Director of the Centers for Disease Control and Pre5 vention, shall directly or through grants, cooperative 

6 agreements, or contracts to eligible entities— 

7 ‘‘(1) conduct, support, and promote the coordi8 nation of research, investigations, demonstrations, 

9 training, and studies relating to the control, preven10 tion, and surveillance of the risk factors associated 

11 with cognitive health, Alzheimer’s disease, and other 

12 dementias; and 

13 ‘‘(2) seek early recognition of, and early inter14 vention in the course of, Alzheimer’s disease and 

15 other dementias. 

16 ‘‘(b) CERTAIN ACTIVITIES.—Activities under sub17 section (a) shall include— 

18 ‘‘(1) providing support for the dissemination 

19 and implementation of the Roadmap to Maintaining 

20 Cognitive Health of the Centers for Disease Control 

21 and Prevention to effectively mobilize the public 

22 health community into action; 

23 ‘‘(2) the development of coordinated public edu24 cation programs, services, and demonstrations which 

25 are designed to increase general awareness of cog26 nitive function and promote a brain healthy lifestyle; 


wwoods2 on DSK1DXX6B1PROD with BILLS
15 

•S 1492 IS

1 ‘‘(3) the development of targeted communica2 tion strategies and tools to educate health profes3 sionals and service providers about the early recogni4 tion, diagnosis, care, and management of Alz5 heimer’s disease and other dementias, and to provide 

6 consumers with information about interventions, 

7 products, and services that promote cognitive health 

8 and assist consumers in maintaining current under9 standing about cognitive health based on the best 

10 science available; and 

11 ‘‘(4) providing support for the collection, publi12 cation, and analysis of data and the prevalence and 

13 incidence of cognitive health, Alzheimer’s disease, 

14 and other dementias, and the evaluation of existing 

15 population-based surveillance systems (such as the 

16 Behavioral Risk Factors Surveillance Survey 

17 (BRFSS) and the National Health Interview Survey 

18 (NHIS)) to identify limitations that exist in the area 

19 of cognitive health, and if necessary, the develop20 ment of a surveillance system for cognitive decline, 

21 including Alzheimer’s disease and other dementias. 

22 ‘‘(c) GRANTS.—The Secretary may award grants 

23 under this section— 

24 ‘‘(1) to State and local health agencies for the 

25 purpose of— 


wwoods2 on DSK1DXX6B1PROD with BILLS
16 

•S 1492 IS

1 ‘‘(A) coordinating activities related to cog2 nitive health, Alzheimer’s disease, and other de3 mentias with existing State-based health pro4 grams and community-based organizations; 

5 ‘‘(B) providing Alzheimer’s disease edu6 cation and training opportunities and programs 

7 for health professionals; and 

8 ‘‘(C) developing, testing, evaluating, and 

9 replicating effective Alzheimer’s disease inter10 vention programs to maintain or improve cog11 nitive health; and 

12 ‘‘(2) to nonprofit private health organizations 

13 with expertise in providing care and services to indi14 viduals with Alzheimer’s disease for the purpose 

15 of— 

16 ‘‘(A) disseminating information to the pub17 lic; 

18 ‘‘(B) testing model intervention programs 

19 to improve cognitive health; and 

20 ‘‘(C) coordinating existing services related 

21 to cognitive health, Alzheimer’s disease, and 

22 other dementias with State-based health pro23 grams. 

24 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For the 

25 purpose of carrying out this section, there are authorized 


wwoods2 on DSK1DXX6B1PROD with BILLS
17 

•S 1492 IS

1 to be appropriated $15,000,000 for fiscal year 2010, and 

2 such sums as may be necessary for each of fiscal years 

3 2011 through 2014.’’. 

4 TITLE III—ASSISTANCE FOR 

5 CAREGIVERS 

6 SEC. 301. ALZHEIMER’S CALL CENTER. 

7 Part P of title III of the Public Health Service Act 

8 (42 U.S.C. 280g et seq.), as amended by section 201, is 

9 further amended by adding at the end the following: 

10 ‘‘SEC. 399V. ALZHEIMER’S CALL CENTER. 

11 ‘‘(a) IN GENERAL.—The Secretary, acting through 

12 the Administration on Aging, shall award a cooperative 

13 grant to a non-profit or community-based organization to 

14 support the establishment and operation of an Alzheimer’s 

15 Call Center that is accessible 24 hours a day, 7 days a 

16 week, at the national and local levels, to provide expert 

17 advice, care consultation, information, and referrals re18 garding Alzheimer’s disease. 

19 ‘‘(b) ACTIVITIES.—The Alzheimer’s Call Center es20 tablished under subsection (a) shall— 

21 ‘‘(1) collaborate with the Administration on 

22 Aging in the development, modification, and execu23 tion of the Call Center’s work plan; 

24 ‘‘(2) assist the Administration on Aging in de25 veloping and sustaining collaborations between the 


wwoods2 on DSK1DXX6B1PROD with BILLS
18 

•S 1492 IS

1 Call Center, the Eldercare Locator of the Adminis2 tration of Aging, and the grantees under the Alz3 heimer’s disease demonstration program under sub4 part II of part K; 

5 ‘‘(3) provide a 24 hours a day, 7 days a week 

6 toll-free call center with trained professional staff 

7 who are available to provide care consultation and 

8 crisis intervention to individuals with Alzheimer’s 

9 disease and other dementias, their family and infor10 mal caregivers, and others as appropriate; 

11 ‘‘(4) be accessible by telephone through a single 

12 toll-free telephone number, website, and e-mail ad13 dress; and 

14 ‘‘(5) evaluate the impact of the Call Center’s 

15 activities and services. 

16 ‘‘(c) MULTILINGUAL CAPACITY.—The Call Center es17 tablished under this section shall have a multilingual ca18 pacity and shall respond to inquiries in at least 140 lan19 guages through its own bilingual staff and with the use 

20 of a language translation service. 

21 ‘‘(d) RESPONSE TO EMERGENCY AND ONGOING

22 NEEDS.—The Call Center established under this section 

23 shall collaborate with community-based organizations, in24 cluding non-profit agencies and organizations, to ensure 

25 local, on-the-ground capacity to respond to emergency and 


wwoods2 on DSK1DXX6B1PROD with BILLS
19 

•S 1492 IS

1 on-going needs of individuals with Alzheimer’s disease and 

2 other dementias, their families, and informal caregivers. 

3 ‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—For the 

4 purpose of carrying out this section, there are authorized 

5 to be appropriated $1,000,000 for fiscal year 2010, and 

6 such sums as may be necessary for each of fiscal years 

7 2011 through 2014.’’. 

8 SEC. 302. INNOVATIVE ALZHEIMER’S CARE STATE MATCH9 ING GRANT PROGRAM. 

10 (a) AUTHORIZATION OF APPROPRIATIONS.—Section 

11 398B(e) of the Public Health Service Act (42 U.S.C. 

12 280c–5(e)) is amended— 

13 (1) by striking ‘‘and such’’ and inserting 

14 ‘‘such’’; and 

15 (2) by inserting before the period the following: 

16 ‘‘, $25,000,000 for fiscal year 2010, and such sums 

17 as may be necessary for each of fiscal years 2011 

18 through 2014’’. 

19 (b) PROGRAM EXPANSION.—Section 398(a) of the 

20 Public Health Service Act (42 U.S.C. 280c–3(a)) is 

21 amended— 

22 (1) in paragraph (2), by inserting after ‘‘other 

23 respite care’’ the following: ‘‘and care consultation, 

24 including assessment of needs, assistance with planVerDate Nov 24 2008 03:06 Jul 23, 2009 Jkt 079200 PO 00000 Frm 00019 Fmt 6652 Sfmt 6201 E:\BILLS\S1492.IS S1492

wwoods2 on DSK1DXX6B1PROD with BILLS
20 

•S 1492 IS

1 ning and problem solving, and providing supportive 

2 listening,’’; 

3 (2) in paragraph (3), by striking ‘‘; and’’ and 

4 inserting the following: ‘‘, and individuals in frontier 

5 areas (in this subsection, defined as areas with 6 or 

6 fewer people per square mile or areas in which resi7 dents must travel at least 60 minutes or 60 miles to 

8 receive health care services);’’; 

9 (3) in paragraph (4), by striking the period at 

10 the end and inserting a semicolon; and 

11 (4) by adding at the end the following: 

12 ‘‘(5) to encourage grantees under this section to 

13 coordinate activities with other State officials admin14 istering efforts to promote long-term care options 

15 that enable older individuals to receive long-term 

16 care in home- and community-based settings, in a 

17 manner responsive to the needs and preferences of 

18 older individuals and their family caregivers; 

19 ‘‘(6) to encourage grantees under this section 

20 to— 

21 ‘‘(A) engage in activities that support early 

22 detection and diagnosis of Alzheimer’s disease 

23 and other dementias; 

24 ‘‘(B) provide training about how Alz25 heimer’s disease can affect behavior and impede 


wwoods2 on DSK1DXX6B1PROD with BILLS
21 

•S 1492 IS

1 communication in medical and community set2 tings to— 

3 ‘‘(i) medical personnel, including hos4 pital staff, emergency room personnel, 

5 home health care workers and physician of6 fice staff; 

7 ‘‘(ii) rehabilitation services providers; 

8 and 

9 ‘‘(iii) caregivers of individuals with 

10 Alzheimer’s disease; 

11 ‘‘(C) develop guidelines to provide the med12 ical community with up-to-date information 

13 about the best methods of care for individuals 

14 with Alzheimer’s disease; 

15 ‘‘(D) inform community physicians about 

16 available resources to assist the physician in de17 tecting and managing Alzheimer’s disease; and 

18 ‘‘(E) raise awareness among community 

19 physicians about the availability of community20 based organizations which can assist individuals 

21 with Alzheimer’s disease and their caregivers; 

22 ‘‘(7) to encourage grantees under this section to 

23 engage in activities that use findings from evidence24 based research on service models and techniques to 


wwoods2 on DSK1DXX6B1PROD with BILLS
22 

•S 1492 IS

1 support individuals with Alzheimer’s disease and 

2 their caregivers; and 

3 ‘‘(8) to encourage grantees under this section to 

4 incorporate best practices for effectively serving indi5 viduals with Alzheimer’s disease in community-based 

6 settings into systems initiatives and long-term care 

7 activities.’’. 

Æ 


wwoods2 on DSK1DXX6B1PROD with BILLS